A Phase 2, multicenter, open-label study to assess safety and preliminary activity of eribulin mesylate in pediatric subjects with relapsed/refractory rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) and Ewing sarcoma (EWS)
Eribulin Mesylate in Pediatric Subjects with Rhabdomyosarcoma (RMS), non-Rhabdomyosarcoma Soft Tissue Sarcoma(NRSTS) and Ewing Sarcoma(EWS)
Sponsor: Eisai
Enrolling: Male and Female Patients
IRB Number: AAAS0709
U.S. Govt. ID: NCT03441360
Contact: Rebecca Zylber, CPNP: 212-305-7212 / rjv2107@cumc.columbia.edu
Additional Study Information: The main purpose of this study is to see if eribulin might work and might be used in the treatment of pediatric subjects with rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) and Ewing sarcoma (EWS) that has either come back or has not responded to the standard therapy. Eribulin will be administered as an intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle.
This study is closed
Investigator
Alice Lee, MD
Do You Qualify?
Is your child 12 months to less than 18 years of age? Yes No
Does your child have relapsed or refractory RMS, NRSTS, or relapsed or refractory EWS? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Rebecca Zylber, CPNP
rjv2107@cumc.columbia.edu
212-305-7212
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE